Table 1. Distribution of patients and parameters correlated with DMFS in discover set.
| Characteristic | No. | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | ||
| Lymph node status | 0.001 | 0.445 | |||||
| Negative | 315 | 1 | 1 | ||||
| Positive | 164 | 1.99 | 0.62–6.37 | 1.58 | 0.49–5.09 | ||
| Unknown | 16 | ||||||
| TLS | < 0.001 | < 0.001 | |||||
| Low-risk | 362 | 1 | 1 | ||||
| High-risk | 133 | 4.04 | 2.83–5.77 | 3.40 | 2.34–4.96 | ||
| Intrinsic subtype | 0.016 | 0.768 | |||||
| Luminal A | 147 | 1 | 1 | ||||
| Others | 348 | 1.68 | 1.10–2.58 | 0.93 | 0.59–1.49 | ||
| Gene21 | < 0.001 | 0.008 | |||||
| Low & medium-risk | 253 | 1 | 1 | ||||
| High-risk | 242 | 2.27 | 1.56–3.29 | 1.72 | 1.15–2.58 | ||
| Gene70 | 0.028 | 0.460 | |||||
| Low-risk | 48 | 1 | 1 | ||||
| High-risk | 447 | 2.63 | 1.08–6.44 | 1.42 | 0.56–3.60 | ||
DMFS=distant metastasis-free survival; HR=hazard ratio; CI=confidence interval; TLS=tamoxifen efficacy-related long noncoding RNA signature; Gene21=21-gene recurrence score; Gene70=70-gene prognosis signature.